Lifitegrast - Shire

Drug Profile

Lifitegrast - Shire

Alternative Names: Lifitegrast; SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer SARcode Bioscience; Shire
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • No development reported Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 27 Oct 2017 Shire anticipates approval for NDS filed for lifitegrast in Dry eyes in Canada by the first quarter of 2018
  • 07 Aug 2017 Preregistration for Dry eyes in United Kingdom, Greece, Spain, Portugal, Italy, France, Netherlands, Germany, Finland, Sweden, Sweden, Norway, Denmark (Ophthalmic)
  • 14 Jun 2017 Efficacay and safety data from pooled analysis in Dry Eyes presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top